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Abstract
Purpose Several cut-off points for trismus in head and neck cancer patients have been used. Amouth opening of 35mm or less is
most frequently used as cut-off point. Due to the variation in cut-off points, prevalence, risk factors and treatment outcomes of
trismus cannot be studied in a uniform manner. To provide uniformity, we aimed to verify the cut-off point of 35 mm or less.
Additionally, we aimed to determine associated covariates with reported difficulties when opening the mouth.
Methods In a cross-sectional design, we measured the mouth opening in 671 head and neck cancer patients at the Department of
Oral andMaxillofacial Surgery, at the University Medical Center Groningen. The cut-off point was determined using the receiver
operating characteristic curve and Youden index, with reported difficulties when opening the mouth as criterion for trismus. Cut-
off points for significant covariates were also determined.
Results The Youden index was highest at 35 mm, with a sensitivity of 0.71 and a specificity of 0.86. Of the covariates analysed,
type of treatment modality was significantly associated with reported difficulties when opening the mouth. The highest Youden
index for patients treated with surgery alone was 37 mm and for patients treated with radiotherapy alone 33 mm.
Conclusions The cut-off point of 35 mm or less for trismus was confirmed in a head and neck cancer population and is
recommended to be used in future studies. Patients receiving different treatment modalities experience difficulty when opening
the mouth differently.
Keywords Head and neck neoplasms .Mouth neoplasms . Surgery, oral . Trismus . Range ofmotion, articular . Quality of life
Introduction
Trismus, a restricted mouth opening, in head and neck cancer
patients may be caused by ingrowth of the tumour in the
masticatory muscles or by fibrosis after surgery or radiother-
apy. Trismus can hamper normal oral intake, dental hygiene,
social activities, oncological follow-up and dental treatment
[1–5].
Different cut-off points have been described for trismus
based on the dental status of patients: 35 mm for dentulous
patients and 40 mm for edentulous patients [2]. Other cut-off
points for trismus are based on the severity of the restriction,
such as 35 mm for moderate trismus and 20 or 25 mm for
severe trismus [6, 7]. Based upon the severity of the restriction,
grades have also been used: grade 2 for a mouth opening of 10
to 20 mm, grade 3 for a mouth opening of 5 to 10 mm and
grade 4 for a mouth opening less than 5 mm [8]. Sometimes
cut-off points seem to be chosen arbitrarily [9]. Due to the
various cut-off points used, risk factors and the effectiveness
of treatment for trismus cannot be analysed in a uniform man-
ner and research results cannot be interpreted easily.
The most commonly used cut-off point is 35 mm or less [1,
10–12]. A study determined this cut-off point on the basis of
perceived restrictions reported by head and neck cancer pa-
tients [13]. The percentage correctly predicted trismus was
81%, with a sensitivity of 0.71 and a specificity of 0.98.
Another study had a similar cut-off point of less than 35 mm
based upon reported problems with chewing and diet [14].
The sample sizes were 89 and 100 patients, resulting in little
or no statistical power to perform covariate analyses.
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The aim of the present study was to verify the cut-off point
of 35 mm or less for trismus in a large head and neck cancer
population. Firstly, we determined the cut-off point for trismus
based upon reported difficulties opening the mouth. Secondly,
we determined cut-off points for significant covariates.
Materials and methods
Patient selection
This cross-sectional study included patients who visited the
Department of Oral and Maxillofacial Surgery at the
University Medical Center Groningen (UMCG) (Netherlands)
for head and neck cancer between November 2012 and January
2015. Patients were included if they had a malignant tumour
located in the upper aero-digestive tract, unknown primaries
with metastases in the head and neck region, or a major salivary
gland tumour. Patients were excluded if theywere younger than
18 years, were not diagnosed with head and neck cancer, had
rare types of tumours, had missing data regarding maximum
mouth opening (MMO) or had missing data regarding reported
difficulties opening the mouth.
Our study was carried out according to the regulations of
our institute. The Medical Ethical Committee of the UMCG
concluded that our research was not subject to the Medical
Research (Human Subject) Act (METc number 2016.692).
MMO measurements and difficulties opening
the mouth
MMO measurements were performed by surgeons, nurse
practitioners or residents, using the OraStretch® Range-of-
Motion Scale, as part of routine patient care. MMO was mea-
sured during every follow-up visit. As patients had several
follow-up visits during the study period, multiple MMO mea-
surements were recorded. In our analysis, we used only the
first recorded MMO measurement of each included patient.
MMO and dental status were recorded on a separate registra-
tion form. If the mouth opening was measured at the right
upper central incisor and the right lower central incisor (of
own dentition or prosthesis), the dental status was recorded
as ‘dentate’. If the alveolar ridges at the former location of the
right upper and lower central incisor were used as measure-
ment points, the dental status was recorded as ‘edentulous’.
If the alveolar ridge was used as the measurement point for
one jaw, and the right upper or lower central incisor for the
other jaw, the dental status was recorded as ‘partially edentu-
lous’. Because the scale of the OraStretch® Range-of-Motion
Scale has a maximum of 52 mm, patients who had a MMO of
52 mm or more were measured using a sliding calliper (mm).
After recording the MMO, the patients were asked if they
experienced difficulties opening the mouth (yes, no).
Additional data
Besides the data on the registration form, additional data was
retrieved from the patient information system used in the
UMCG, including cT classification based on the Union for
International Cancer Control (UICC) TNM classification
2009 (TX, T1–2, T3–4, unknown), tumour localisation
(tongue, floor of mouth, maxilla (including the maxilla, hard
palate and maxillary sinus), mandible, cheek, major salivary
glands (including the parotid gland, submandibular gland and
sublingual gland), oropharynx (including the oropharynx, ba-
se of tongue, retromolar space, tonsils and soft palate), hypo-
pharynx and larynx, lip, unknown primary) and treatment mo-
dalities (no treatment, surgery alone, radiotherapy alone, com-
bination of surgery and radiotherapy). Patients were recorded
as having received radiotherapy if they received primary ra-
diotherapy or a combination of radiotherapy and
chemotherapy.
Primary analysis
Data was analysed using a receiver operating characteristic
(ROC) curve, in which MMO was compared to the patients’
reported difficulties opening the mouth. Based on the ROC
curve, we calculated the AUC, sensitivity, specificity and
Youden index. We determined the discriminant validity
of patients reporting difficulties opening the mouth to
be perfect if the area under the curve (AUC) was 1,
highly accurate if ≥ 0.9, moderately accurate if 0.7 ≥
AUC < 0.9, less accurate if 0.5 ≥ AUC < 0.7 and non-
informative if the AUC was 0.5 [15]. The Youden index
was calculated as follows: (sensitivity + specificity) − 1
[16]. We determined a cut-off point for trismus on the
basis of the highest Youden index score.
Covariate analysis
We used a t test for independent samples to analyse an asso-
ciation between reported difficulties opening the mouth and
age and a χ2 test to analyse associations between reported
difficulties opening the mouth and sex, dental status and dif-
ferent treatment modalities. When a significant association
between reported difficulties opening the mouth and a covar-
iate was found (p < 0.05), separate ROC curves were plotted
for that covariate. Cut-off points for the subgroups of that
covariate were determined in the same way as for the total
group.
Post hoc analysis
In case the results of the performed analyses need more





MMOof 839 patients was recorded. In total, 168 patients were
excluded because they were not diagnosed with head and neck
cancer (n = 77), had rare types of tumours concerning
localisations (for example pyriform sinus, ethmoid sinus,
sphenoid sinus), metastases of primary tumours that were
not part of head and neck oncology (for example mamma or
kidney), or histology (neuroblastoma, lymphoma, Merkel cell
carcinoma) or a combination (n = 29), or had missing data
regardingMMOmeasurement or reported difficulties opening
the mouth (n = 62). In total, 134 patients had a MMO larger
than 52 mm, of whom 109 were measured using a sliding
calliper. Of 25 patients, the MMO was set on 52 mm
because a sliding calliper was unavailable during the
visit. The final study population consisted of 671 pa-
tients (80.0%) (Table 1). In our final study population,
278 patients (41.4%) were treated with surgery alone, 130
patients (19.4%) were treated with radiotherapy alone and
215 patients (32.1%) were treated with a combination of
surgery and radiotherapy.
MMO measurements versus difficulties opening
the mouth
In total, 109 (16.2%) patients reported difficulties opening the
mouth. These patients had a mean MMO of 30.1 mm (95%
confidence interval (CI) 28.0 to 32.1 mm) (Fig. 1a). Patients
Table 1 Patient, tumour and




Patient characteristics n (%) n (%) n (%)
Male 360 (53.7) 143 (51.4) 82 (63.1)
Age (years), range 11–96 (mean; SD) 63.4 (13.5) 62.6 (13.7) 63.9 (11.3)
Maximum mouth opening, range 7–73 (mean; SD) 42.2 (10.6) 45.0 (8.8) 41.3 (11.1)
Dental status
Fully dentulous 526 (78.4) 234 (84.2) 95 (73.1)
Fully edentulous 99 (14.8) 33 (11.9) 25 (19.2)
Partially edentulous 42 (6.3) 9 (3.2) 10 (7.7)
Missing 4 (0.6) 2 (0.7) 0 (0.0)
Tumour characteristics
Localisation of primary tumour
Tongue 148 (22.1) 89 (32.0) 7 (5.4)
Floor of mouth 82 (12.2) 39 (14.0) 13 (10.0)
Maxilla 34 (5.1) 17 (6.1) 7 (5.4)
Mandible 49 (7.3) 23 (8.3) 1 (0.8)
Cheek 19 (2.8) 8 (2.9) 1 (0.8)
Major salivary glands 70 (10.4) 30 (10.8) 5 (3.8)
Oropharynx 94 (14.0) 24 (8.6) 45 (34.6)
Hypopharynx and larynx 32 (4.8) 0 (0.0) 24 (18.5)
Lip 52 (7.7) 27 (9.7) 14 (10.8)
Unknown primary 12 (1.8) 2 (0.7) 8 (6.2)
Missing 79 (11.8) 19 (6.8) 5 (3.8)
T classification
TX 9 (1.3) 1 (0.4) 2 (1.5)
T1, T2 410 (61.1) 230 (82.7) 60 (46.2)
T3, T4 143 (21.3) 18 (6.5) 56 (43.1)
Missing 109 (16.2) 29 (10.4) 12 (9.2)
Treatment characteristics
No treatment 48 (7.2) 0 (0.0) 0 (0.0)
Surgery 278 (41.4) 278 (100.0) 0 (0.0)
Radiotherapy 130 (19.4) 0 (0.0) 130 (100.0)
Combination of surgery and radiotherapy 215 (32.1) 0 (0.0) 0 (0.0)
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who reported no difficulties opening the mouth had a mean
MMO of 44.5 mm (95% CI 43.8 to 45.2 mm).
Primary analysis
The AUC of the ROC curve of the total study population was
0.846 (95% CI 0.803 to 0.889) (Fig. 2a). The Youden index
was highest at 35 mm (0.569) with a sensitivity of 0.706 and a
specificity of 0.863 (Table 2).
Fig. 1 Box-and-whisker plots concerning maximum mouth opening in
relation to patients’ perception of experiencing difficulties opening the
mouth. a Total study population, b patients treated with surgery only,
c patients treated with radiotherapy only
Fig. 2 Receiver operating characteristic curve comparing maximum
mouth opening (mm) with reported difficulties opening the mouth.
a ROC curve for the total study population. Area under the curve:
0.846 (95% CI 0.803 to 0.889). b ROC curve for surgery only.
Area under the curve: 0.784 (95% CI 0.667 to 0.901). c ROC




No significant difference in age was found between patients
who reported difficulties opening the mouth and those who
did not (p = 0.804). No significant difference was found in sex
(p = 0.756) and in dental status (p = 0.439) between patients
who reported difficulties opening the mouth and those who
did not. Patients who were treated with radiotherapy alone
experienced difficulties opening the mouth more often than
patients who were treated with surgery alone (p < 0.001)
(Table 3).
We plotted a ROC curve for patients who were treated with
surgery alone and patients who were treated with radiotherapy
alone (Fig. 2b, c). The AUC of the ROC curve for surgery
alone was 0.784 (95% CI 0.667 to 0.901). The Youden
index was highest at a MMO of 37 mm (0.496), with a
sensitivity of 0.636 and a specificity of 0.859 (Table 2).
The AUC of the ROC curve for radiotherapy alone was
0.811 (95% CI 0.705 to 0.917). The Youden index was
highest at a MMO of 33 mm (0.560), with a sensitivity
of 0.667 and a specificity of 0.893.
Post hoc analysis
To provide insight into the possible association between the
time from treatment (surgery or radiotherapy) to measurement
and reported difficulties opening the mouth (yes, no), we per-
formed additional analysis. Mann–Whitney U test showed
that the period from treatment to measurement differs signif-
icantly in relation to reported difficulties opening the mouth
(p = 0.010) and in relation to treatment modality (surgery or
radiotherapy) (p < 0.001) (Table 4). In the multivariate logistic
regression analysis, treatment modality was significantly as-
sociated with reported difficulties opening the mouth
(p = 0.005), but the period from treatment to measurement
does not (p = 0.569).
Table 2 Sensitivity, specificity and Youden index for maximum mouth opening measurements
Cut-off point
(mm)
Total study population (n = 671) Surgery only (n = 278) Radiotherapy only (n = 130)
Sensitivity Specificity J Sensitivity Specificity J Sensitivity Specificity J
20 0.202 0.988 0.189 0.091 0.992 0.083 0.259 0.990 0.250
21 0.229 0.988 0.217 0.091 0.992 0.083 0.259 0.990 0.250
22 0.266 0.986 0.252 0.091 0.992 0.083 0.370 0.990 0.361
23 0.284 0.980 0.265 0.091 0.992 0.083 0.370 0.990 0.361
24 0.312 0.980 0.292 0.091 0.992 0.083 0.407 0.990 0.398
25 0.330 0.980 0.311 0.091 0.992 0.083 0.444 0.990 0.435
26 0.394 0.977 0.371 0.091 0.992 0.083 0.444 0.981 0.425
27 0.413 0.973 0.386 0.182 0.984 0.166 0.444 0.981 0.425
28 0.468 0.959 0.427 0.182 0.977 0.158 0.481 0.971 0.452
29 0.505 0.950 0.455 0.273 0.969 0.241 0.519 0.961 0.480
30 0.523 0.940 0.462 0.273 0.961 0.234 0.556 0.951 0.507
31 0.624 0.916 0.540 0.409 0.961 0.370 0.630 0.893 0.523
32 0.642 0.909 0.551 0.455 0.957 0.412 0.630 0.893 0.523
33 0.661 0.902 0.563 0.500 0.949 0.449 0.667 0.893 0.560a
34 0.688 0.874 0.562 0.500 0.918 0.418 0.704 0.845 0.548
35 0.706 0.863 0.569a 0.545 0.910 0.456 0.704 0.835 0.539
36 0.716 0.845 0.561 0.545 0.898 0.444 0.704 0.816 0.519
37 0.761 0.786 0.548 0.636 0.859 0.496a 0.704 0.767 0.471
38 0.771 0.760 0.530 0.636 0.816 0.453 0.704 0.748 0.451
39 0.780 0.747 0.527 0.682 0.805 0.487 0.704 0.718 0.422
40 0.807 0.698 0.505 0.727 0.750 0.477 0.704 0.689 0.393
41 0.817 0.681 0.498 0.727 0.730 0.458 0.741 0.670 0.411
42 0.826 0.653 0.479 0.727 0.699 0.426 0.741 0.641 0.382
43 0.862 0.544 0.407 0.773 0.594 0.366 0.778 0.544 0.321
44 0.899 0.527 0.426 0.818 0.570 0.388 0.852 0.544 0.396
45 0.908 0.500 0.408 0.818 0.547 0.365 0.852 0.505 0.357
J Youden index
aHighest Youden index score
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As we found a 4-mm difference between the cut-off
points for different treatment modalities, we performed
a Mann–Whitney U test in order to give insight into a
possible association between treatment modalities and
the influence on MMO. The test showed that the
MMO was not significantly different after surgery
alone or radiotherapy alone for the patients who report-




For the total study population, the cut-off point for tris-
mus was 35 mm or less. For patients who were treated
with surgery alone, the cut-off point was 37 mm or less
and for patients who received radiotherapy alone 33 mm
or less.
Table 3 Comparison between
patients with and without







n % n % χ2 df p
Male sex 303 53.9 57 52.3 0.096 1 0.756
Dental status 1.646 2 0.439
Dentate 445 79.7 81 74.3
Partially edentulous 34 6.1 8 7.3
Edentulous 79 14.2 20 18.3
Treatment modality 33.528 3 < 0.001
No treatment 44 7.8 4 3.7
Surgery only 256 45.6 22 20.2
Radiotherapy only 103 18.3 27 24.8
Surgery and radiotherapy 159 28.3 56 51.4
Mean SD Mean SD DM 95% CI p
Age 63.4 13.7 63.7 12.4 − 0.35 − 3.1 to 2.4 0.804a
% column percentage, χ2 results of chi-square test, df degrees of freedom, DM difference in means
a t test for independent samples
Table 4 Analysis of time from treatment to measurement (months) in
patients with and without difficulties opening the mouth and in patients
who had surgery only or radiotherapy only and analysis of maximal
mouth opening measurement, only of patients who reported difficulties
when opening the mouth, who had surgery only or radiotherapy only,
using the Mann–Whitney U test
No difficulties opening the
mouth (n = 399)
Difficulties opening the
mouth (n = 92)
Median IQR Median IQR MWU p
Time from treatment
to measurementa
28.2 8.9; 58.3 16.1 2.1; 48.0 15,174.0 0.010
Surgery only (n = 220) Radiotherapy only (n = 80)
Median IQR Median IQR MWU p
Time from treatment
to measurementa
33.9 12.6; 67.4 9.6 1.5; 31.7 4856.5 < 0.001
Surgery only (n = 22) Radiotherapy only (n = 27)
Median IQR Median IQR MWU p
Maximal mouth opening
measurementb
34.0 29.0; 43.3 29.0 20.0; 43.0 209.5 0.078
IQR interquartile range, MWUMann–Whitney U test
a 48 patients received no treatment, 132 received treatment after the measurement moment
b Only the patients are included who reported difficulties when opening the mouth
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Interpretation
We found that patients who were treated with radiotherapy
alone experienced difficulties opening the mouth at a smaller
mouth opening (33 mm) compared to patients who were treat-
ed with surgery alone (37 mm). Postoperative symptoms, such
as pain, scarring and trismus, are immediately noticeable for
the patient. After radiotherapy, MMO decreases more gradu-
ally [17]. On average, during radiotherapy (first 9 weeks), the
MMO decreased with 1.3% per month. In the first 9 months
after radiotherapy, the MMO decreased 2.4% per month.
Between 12 and 24 months after radiotherapy, the MMO de-
creased 0.2% per month. This gradual decrease in MMO was
also confirmed in another study [18]. The prevalence of tris-
mus in head and neck cancer patients after radiotherapy treat-
ment was 31.9% after 3 months, 34.04% after 6 months and
38.39% after 12 months. As the MMO decreases gradually,
patients have the ability to adapt in the meantime and therefore
may experience mouth opening restrictions at a smaller mouth
opening.
Our assumption that patients adapt to limited mouth open-
ing in time is confirmed in our data, as the period from treat-
ment to measurement is significantly associated with reported
difficulties opening the mouth. Taking the treatment modality
into account, in a multivariate logistic regression analysis, the
period from treatment to measurement was not significantly
associated with reported difficulties opening the mouth.
Therefore, for clinical use, the treatment modality alone
should be taken into account for perceived difficulties when
opening the mouth.
We observed a 4-mm difference between the cut-off points
of different treatment modalities, but we also found thatMMO
was not significantly different after surgery alone or radiother-
apy alone for the patients who reported difficulties when
opening the mouth. Therefore, we prefer to speak of a trend
for earlier reporting of difficulties when opening the mouth in
patients treated with surgery alone compared to patients
receiving radiotherapy alone.
Other studies
One study also determined the cut-off of 35 mm or less. That
study performed an additional covariate analyses for dental
status only, but did not find a significant difference [13]. We
were able to analyse other covariates: we found a significant
difference regarding treatment modalities as covariates, but
not for dental status. A second study determined the cut-off
point for trismus on the basis of reported problems with
chewing and diet. This study determined the cut-off point of
less than 34 mm. They determined the cut-off point in groups
of 5 mm instead of 1 mm, which could therefore have resulted
into a different cut-off point compared to our study. They did
not perform additional covariate analyses [14].
Study limitations and strengths
A limitation of our study is that MMO was measured at dif-
ferent time intervals in regard to the patients’ cancer treatment,
as MMO was measured during regular appointments at the
Department of Oral and Maxillofacial Surgery of Groningen.
For example, one patient had a measurement 3 months post-
treatment, while another patient had ameasurement 24months
post-treatment. This difference could have led to an underes-
timation of patients who reported difficulties opening the
mouth, as some patients could already have adapted to their
new MMO and would not report difficulties opening the
mouth.
Another possible limitation is that several professionals
measured maximum mouth opening, which could have intro-
duced an inter-observer measurement error. Nonetheless, a
previous study shows that inter-observer variability is minimal
[19].
As the sliding calliper was not always available during the
MMO measurements, 25 patients could not be measured.
Their MMO was set on 52 mm. We expect that the patients
with a MMO larger than 52 mm do not experience difficulties
when opening the mouth. The results of the mean MMO of
patients who do not experience difficulties when opening the
mouth might therefore be slightly lower than the actual mean
MMO.
The strength of our study is the large study population and
MMOmeasurements. Due to our large database, we were able
to perform covariate analyses with enough statistical power.
Due to our covariate analyses, we were able to make a
distinction between the patients’ perception of having
difficulties when opening the mouth after receiving ra-
diotherapy or surgery. Now clinicians can take into ac-
count that patients’ perception of a restricted mouth
opening differ after surgery or radiotherapy. As the cut-off
point of 35 mm or less is now confirmed in a large head and
neck cancer population, clinicians could use this cut-off
point as an indicator to start preventive measures. We
recommend to use this cut-off point for future research
as well; to explore risk factors of trismus, to report
prevalence of trismus and for evaluating the effectiveness
of trismus treatment.
Conclusion
We have verified the cut-off point of 35 mm or less for trismus
in the total head and neck cancer population. Patients receiv-
ing different treatment modalities could differ in their percep-
tion of difficulties in opening their mouth. To improve com-
parison of future studies concerning trismus in head and neck
cancer patients, we recommend using the cut-off point of
35 mm or less.
Support Care Cancer
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